Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesWhat happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy
Indian Journal of Urology, 06/26/09
Maheshwari R et al. - Study highlights the fact that patients with muscle-invasive bladder cancer refusing cystectomy after chemotherapy are at high risk for disease-related mortality. At the same time, pts with small, clinically confined single tumors, which can be visibly and microscopically completely resected before neoadjuvant chemotherapy, are most likely to survive without cystectomy.
Methods- A prospective study to determine the outcome of pts who refuse cystectomy after receiving neoadjuvant chemotherapy
- 63 such pts evaluated between 1995-2001
- Tumor and treatment features for a median f/u of 86 mo was assessed, all pts being followed-up for >5 yrs
- 40 pts (64%) survived, with 54% of them having an intact functioning bladder
- The number and size of invasive tumors were strongly associated with overall survival
- The most significant treatment variable predicting better survival was complete resection of the invasive tumor on restaging transurethral resection (TUR) before starting chemotherapy
- Of 23 pts (36%) who subsequently died of disease, 19 (30%) relapsed with invasive cancer in bladder
- Over 90% of the surviving pts had solitary, small and low-stage invasive tumors completely resected; 83% survived w/o relapses in the bladder
Today in Bladder...keeping you current
Receive free subspecialty "5-minute updates" via email
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: Evaluation of efficacy and tolerance
Journal of Clinical Oncology, 10/26/09
Fesoterodine: a new antimuscarinic for overactive bladder
Aging Health, 10/13/09
Frequently asked questions in the evaluation and management of overactive bladder
The Journal of Family Practice, 11/02/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/14/09
Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy
Annals of Oncology, 10/16/09
Article Search
Sponsor